Global Amyotrophic Lateral Sclerosis Market Overview
Amyotrophic Lateral Sclerosis Market Size was valued at USD 0.75 billion in 2022. The Amyotrophic Lateral Sclerosis market industry is projected to grow from USD 0.79 Billion in 2023 to USD 1.13 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.10% during the forecast period (2023 - 2030). Patients' knowledge of the condition is becoming more widespread, and the elderly population is growing are the key market drivers enhancing the Amyotrophic Lateral Sclerosis market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Patients' understanding of the condition is getting more prevalent, and the growth in the older population is one of the important market drivers that is helping to boost the growth of the amyotrophic lateral sclerosis market. The increasing incidence of amyotrophic lateral sclerosis (ALS) can be attributed to a number of different factors, such as the aging population, genetics, and environmental conditions. It is projected that the prevalence of ALS will increase as the population ages, which will increase the requirement for effective treatments.
The growing prevalence of the disease is anticipated to drive growth in the market for ALS therapies. This is because more people are being diagnosed with the ailment, which means that more people will need treatment. As the number of people diagnosed with ALS rises, there is a greater emphasis placed on discovering new medicines, raising finances and awareness for ALS research, and focusing on the condition more generally. All of these factors contribute to the expansion of the market.
The growing incidence of amyotrophic lateral sclerosis will have a considerable impact on the expansion of the market's growth during the next few years. The rising expense of medical care is another significant aspect that has a significant impact on the market for amyotrophic lateral sclerosis (ALS) treatments. In addition, the amyotrophic lateral sclerosis (ALS) business will grow as a result of advancements in medical technology, increased attempts to raise awareness by both public and private organizations, and rising backing from the government.
The market for treatments for amyotrophic lateral sclerosis (ALS) is expected to rise at a quicker rate due to additional factors such as an increased desire for treatments that are effective and an aging population. The market for amyotrophic lateral sclerosis (ALS) will also expand as a result of an increase in the proportion of people who lead sedentary lifestyles and increased discretionary spending.
In a study published in July 2023, researchers found that utilizing two medications, one of which was already licensed for multiple sclerosis, to target the autoimmune inflammation associated with amyotrophic lateral sclerosis (ALS) was a viable strategy to treatment. Immune cells from sporadic ALS patients were treated with dimethyl fumarate (DMF) and compound H-151 by researchers at UCLA's Department of Integrative Biology and Physiology. DMF is a medication that has been authorized for use in MS treatment. In experimental studies, H-151 has been demonstrated to prevent autoimmunity.
Amyotrophic Lateral Sclerosis Market Trends
- Rising prevalence of ALS to boost market growth
Many variables, including the aging population, genetics, and environmental conditions, contribute to the rising prevalence of ALS. The prevalence of ALS is anticipated to rise as the population ages, increasing the need for efficient therapies. As more people are diagnosed with the condition and require Treatment, the rising prevalence of the disease is projected to propel the market for ALS therapies. As ALS cases rise, greater emphasis is placed on finding better therapies, raising funds and awareness for ALS research, and focusing on the condition more generally, all of which contribute to the market's expansion. According to the National Institute of Neurological Disorders and Stroke (NINDS), persons with ALS frequently pass away from respiratory failure within 3 to 5 years after gradually losing their ability to move. It also notes that of the two forms of ALS, familial ALS makes up the majority of cases in the United States (90–95%), while sporadic ALS accounts for the remainder. Thus, this factor is driving the Amyotrophic Lateral Sclerosis market CAGR.
Additionally, according to an article titled "Estimated Prevalence and Incidence of Amyotrophic Lateral Sclerosis and SOD1 and C9orf72 Genetic Variants" that was published in Neuroepidemiology Journal in July 2021, the combined prevalence rates (per 100,000 people) and incidence rates (per 100,000 person-years) for Europe, North America, Latin America, Asia-Pacific countries, and Japan were 6.22 and 2.31, 5.20 and 2.35, 3.41 and 1.25 The prevalence and incidence of the condition are predicted to rise, which would raise demand for treatments and the market's expansion.
Key players' partnerships, collaborations, product innovations, and rising product approval rates all contribute to the market's expansion. To treat familial amyotrophic lateral sclerosis (ALS) and Friedreich's ataxia, CRISPR Therapeutics and CapsidaBiotherapeutics Inc., for example, entered into a strategic partnership in June 2021. The partnership aims to conduct research and develop, produce, and market in vivo gene editing therapies using CRISPR technology and engineered AAV vectors. Such alliances will probably support market expansion. Thus, this aspect is anticipated to accelerate coffee market revenue globally.
Amyotrophic Lateral Sclerosis Market Segment Insights
Amyotrophic Lateral Sclerosis Type Insights
The Amyotrophic Lateral Sclerosis market segmentation based on type includes Sporadic ALS and Familial ALS. The Sporadic ALS segment held the majority share in 2022, contributing around ~65-67% to the Amyotrophic Lateral Sclerosis market revenue. 90% to 95% of instances of ALS are of the most common kind, called sporadic ALS. Muscle atrophy and weakness deteriorate due to the degeneration of motor neurons in the spinal cord and brain. Although the cause of sporadic ALS is unclear, research suggests that a combination of genetic and environmental factors may be at play. Spontaneous ALS, in contrast to familial ALS, develops in persons without a family history of the illness and is brought on by inherited genetic alterations.
Figure 1: Amyotrophic Lateral Sclerosis Market, by Type, 2022 & 2030 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Amyotrophic Lateral Sclerosis Treatment Insights
Based on Treatment, the Amyotrophic Lateral Sclerosis market segmentation includes Medication, Physical Therapy, and Speech Therapy. The Medication segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. As there is no cure for ALS, available treatments mainly aim to reduce symptoms and enhance the quality of life. The U.S. Food and Drug Administration (FDA) has authorized several drugs to manage ALS. Riluzole, Edaravone, and Nuedexta are a few of them. Other symptoms, including pain, stiffness, and sleeplessness, may also be treated with these drugs. Moreover, physical, occupational, and speech therapy can assist with swallowing and communication issues and maintain muscular strength and function. Hence, the rising pharmaceutical industry positively impacts market growth.
Amyotrophic Lateral Sclerosis End-User Insights
End-User has bifurcated the Amyotrophic Lateral Sclerosis market data into Hospitals, Specialty Centers, Research and Academics Institutes and others. The minimally invasive spine surgery segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period 2022-2030. The need for several hospital stays and visits during Amyotrophic Lateral Sclerosis treatment aids this market's expansion. Patients highly prefer both hospital pharmacies and retail pharmacies. This is explained by the simple and quick access to a wide selection of medications and sufficient goods in the stock made available by these distribution channels.
Amyotrophic Lateral Sclerosis Regional Insights
By Region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North America Amyotrophic Lateral Sclerosis market accounted for USD 0.34 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. Each year, ALS claims the lives of about 1,000 Canadians. Similar numbers of Canadians receive an ALS diagnosis each year. The illness is more prevalent in males than women in the United States and affects people of all colors and ethnicities. Most ALS cases are sporadic, which means they develop in individuals with no documented family history of the condition; however, around 10% of instances are inherited (familial ALS). The expansion in market revenue is driven by an increase in the number of persons diagnosed with the condition and the creation of novel therapies. The main factors influencing the market's growth are the rising awareness of ALS and the creation of novel medications and treatments.
In August 2023, researchers at Oregon Health & Science University showed for the first time that modifying immune cells can reduce the progression of ALS by using a mouse model and confirming their findings with ALS-affected human brain tissue donated after death. Previous findings indicating immune cells might play a role in ALS were contradicted by the identification of a specific type of protein generated on immune cells in the brains and spinal cords of ALS patients through the use of a high-throughput screening approach.
Figure 2: AMYOTROPHIC LATERAL SCLEROSIS MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
During the projected period, the amyotrophic lateral sclerosis market in Europe is anticipated to see high revenue CAGR growth. In the upcoming years, the market for therapies for Amyotrophic Lateral Sclerosis (ALS) is anticipated to expand in Europe due to factors such as an aging population, rising illness awareness, and the creation of new medications. The European Medicines Agency (EMA) has only authorized Riluzole as a treatment for ALS. The medication, sold by Sanofi under the trade name Rilutek, is a glutamatergic antagonist that slows the disease's course by lowering the degree of excitotoxicity, which is the process that causes nerve cells to die. Also, current clinical trials are testing brand-new treatments. Further, the Germany Amyotrophic Lateral Sclerosis market held the largest market share, and the UU.K.Amyotrophic Lateral Sclerosis market was the fastest growing market in the European Region.
During the forecast period, the Asia Pacific market for amyotrophic lateral sclerosis is anticipated to grow steadily in revenue. Due to their enormous patient populations and high healthcare costs, nations like Japan, China, and South Korea are predicted to have rapid market revenue growth. Due to its elderly population and high healthcare spending, Japan has a sizable market for Amyotrophic Lateral Sclerosis (ALS) therapies. The demand for ALS therapies is projected to increase because Japan has one of the highest incidence rates of the condition worldwide. In addition, several novel medications and combination treatments in development are anticipated to influence Japan's market expansion greatly. Moreover, China's Amyotrophic Lateral Sclerosis market held the largest market share, and the India Amyotrophic Lateral Sclerosis market was the fastest-growing market in the Asia-Pacific region.
Amyotrophic Lateral Sclerosis Key Market Players & Competitive Insights
Leading market players are investing a lot of money in R&D to expand their product portfolios, which will spur further market growth for Amyotrophic Lateral Sclerosis. With significant industry changes, including new product releases, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations, market developments are also undertaking various strategic activities to expand their presence. To grow and remain in a market that is becoming increasingly competitive, Amyotrophic Lateral Sclerosis industry competitors must provide affordable products.
Manufacturing locally to cut operational costs is one of the main business tactics the Amyotrophic Lateral Sclerosis industry uses to serve customers and increase the market sector. The Amyotrophic Lateral Sclerosis industry has recently given medicine some of the most important advantages. The Amyotrophic Lateral Sclerosis market major player such as Medtronic Inc (Ireland), Abbott Laboratories (UU.S., Stryker Corporation (U.S. and others are working on expanding the market demand by investing in research and development activities.
A division of Mitsubishi Chemical Holdings Company, Mitsubishi Tanabe Pharma Corporation is an Osaka-based pharmaceutical corporation. Mitsubishi-Tokyo Pharmaceuticals and Welfide Company merged to become Mitsubishi Pharma Corporation in 2001. According to Mitsubishi Tanabe Pharma America, the United States Food and Drug Administration approved RADICAVA ORS (edaravone) for the Treatment of amyotrophic lateral sclerosis in May 2022.
Cambridge, Massachusetts, is home to the biotech business Amylyx Pharmaceuticals, Inc. The main product of Amylyx is AMX0035, an investigational treatment for Amyotrophic Lateral Sclerosis. Amylyx Pharmaceuticals, Inc. said in June 2022 that Health Canada had granted ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine) conditional approval for the Treatment of amyotrophic lateral sclerosis. ALS patients who received ALBRIOZA (also known as AMX0035), either as a stand-alone drug or when paired with other ALS medications, exhibited a statistically significant and clinically important improvement in functional outcomes compared to persons who took a placebo, according to clinical data. This choice marks Amylyx's first authorization for the commercialization of ALBRIOZA.
Key Companies in the Amyotrophic Lateral Sclerosis market include
Sun Pharmaceutical (India)
Mitsubishi Tanabe Pharma America (U.S.)
Covis Pharma (Switzerland)
Ionis Pharmaceutical (UU.S)
ITF Pharma (UU.S)
Ascend Pharmaceuticals LLC (UU.S)
Apotex Inc. (Canada)
Amyotrophic Lateral Sclerosis Industry Developments
June 2022:Canada approved Amylyx Pharmaceuticals Inc.'s new drug ALBRIOZA (AMX0035) for amyotrophic lateral sclerosis.
June 2021:Using fully integrated Adeno-Associated Virus (AAV) engineering, cargo development, and manufacturing, Capsida Biotherapeutics Inc. and CRISPR Therapeutics, two biopharmaceutical companies dedicated to developing novel gene-based treatments for crippling diseases, today announced a strategic partnership to study, develop, produce, and market in vivo gene editing treatments delivered using AAV vectors for the Treatment of familial Amyotrophic Lateral Sclerosis (ALS) and other debilitating diseases
Amyotrophic Lateral Sclerosis Market Segmentation
Amyotrophic Lateral Sclerosis Type Outlook
Sporadic ALS (SALS)
Familial ALS (FALS)
Amyotrophic Lateral Sclerosis Treatment Outlook
Amyotrophic Lateral Sclerosis End-User Outlook
Amyotrophic Lateral Sclerosis Regional Outlook
Rest of Europe
Rest of Asia-Pacific
Rest of the World
|Market Size 2022
||USD 0.75 billion
|Market Size 2023
||USD 0.79 billion
|Market Size 2030
||USD 1.13 billion
|Compound Annual Growth Rate (CAGR)
|Market Forecast Period
||2019 - 2021
|Market Forecast Units
||Value (USD Billion)
||Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
||Product Type, Operating Platforms, and Region
||North America, Europe, Asia Pacific, and the Rest of the World
||The U.S, Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
|Key Companies Profiled
||Sun Pharmaceutical (India), Mitsubishi Tanabe Pharma America (UU.S., Biogen (UU.S., Sanofi (France), Mylan NN.V.(UU.S., Covis Pharma (Switzerland), Ionis Pharmaceutical (UU.S., ITF Pharma (UU.S., Ascend Pharmaceuticals LLC (UU.S., Apotex Inc. (Canada).
|Key Market Opportunities
||Developing healthcare infrastructure
|Key Market Dynamics
||Rise in awareness about the disease among patients Rise in the geriatric population
Frequently Asked Questions (FAQ) :
The Amyotrophic Lateral Sclerosis market size was valued at USD 0.75 Billion in 2022.
The market is projected to grow at a CAGR of 6.10% during the forecast period, 2022-2030.
North America had the largest share of the market
The key players in the market are Sun Pharmaceutical (India), Mitsubishi Tanabe Pharma America (UU.S., Biogen (UU.S., Sanofi (France), Mylan NN.V.(UU.S., Covis Pharma (Switzerland), Ionis Pharmaceutical (UU.S., ITF Pharma (UU.S., Ascend Pharmaceuticals LLC (UU.S., Apotex Inc. (Canada).
The Sporadic Amyotrophic Lateral Sclerosis category dominated the market in 2022.
The medication had the largest share in the Amyotrophic Lateral Sclerosis market.
Key Questions Answered
Request Free Sample
- ✅Global Market Outlook
- ✅In-depth analysis of global and regional trends
- ✅Analyze and identify the major players in the market, their market share, key developments, etc.
- ✅To understand the capability of the major players based on products offered, financials, and strategies.
- ✅Identify disrupting products, companies, and trends.
- ✅To identify opportunities in the market.
- ✅Analyze the key challenges in the market.
- ✅Analyze the regional penetration of players, products, and services in the market.
- ✅Comparison of major players’ financial performance.
- ✅Evaluate strategies adopted by major players.
Why Choose Market Research Future?
Speak to Analyst
- ✅Vigorous research methodologies for specific market.
- ✅Knowledge partners across the globe
- ✅Large network of partner consultants.
- ✅Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- ✅Trusted by fortune 500 companies/startups/universities/organizations
- ✅Large database of 5000+ markets reports.
- ✅Effective and prompt pre- and post-sales support.